212 related articles for article (PubMed ID: 20350190)
1. Effect of vaccination with modified vaccinia Ankara (ACAM3000) on subsequent challenge with Dryvax.
Seaman MS; Wilck MB; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Noble LC; Kleinjan JA; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1353-60. PubMed ID: 20350190
[TBL] [Abstract][Full Text] [Related]
2. Safety and immunogenicity of modified vaccinia Ankara (ACAM3000): effect of dose and route of administration.
Wilck MB; Seaman MS; Baden LR; Walsh SR; Grandpre LE; Devoy C; Giri A; Kleinjan JA; Noble LC; Stevenson KE; Kim HT; Dolin R
J Infect Dis; 2010 May; 201(9):1361-70. PubMed ID: 20350191
[TBL] [Abstract][Full Text] [Related]
3. Enhanced immunogenicity and protective effect conferred by vaccination with combinations of modified vaccinia virus Ankara and licensed smallpox vaccine Dryvax in a mouse model.
Meseda CA; Garcia AD; Kumar A; Mayer AE; Manischewitz J; King LR; Golding H; Merchlinsky M; Weir JP
Virology; 2005 Sep; 339(2):164-75. PubMed ID: 15993917
[TBL] [Abstract][Full Text] [Related]
4. Safety, immunogenicity and efficacy of modified vaccinia Ankara (MVA) against Dryvax challenge in vaccinia-naïve and vaccinia-immune individuals.
Parrino J; McCurdy LH; Larkin BD; Gordon IJ; Rucker SE; Enama ME; Koup RA; Roederer M; Bailer RT; Moodie Z; Gu L; Yan L; Graham BS;
Vaccine; 2007 Feb; 25(8):1513-25. PubMed ID: 17126963
[TBL] [Abstract][Full Text] [Related]
5. Safety and immunogenicity of modified vaccinia Ankara in hematopoietic stem cell transplant recipients: a randomized, controlled trial.
Walsh SR; Wilck MB; Dominguez DJ; Zablowsky E; Bajimaya S; Gagne LS; Verrill KA; Kleinjan JA; Patel A; Zhang Y; Hill H; Acharyya A; Fisher DC; Antin JH; Seaman MS; Dolin R; Baden LR
J Infect Dis; 2013 Jun; 207(12):1888-97. PubMed ID: 23482644
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 Efficacy Trial of Modified Vaccinia Ankara as a Vaccine against Smallpox.
Pittman PR; Hahn M; Lee HS; Koca C; Samy N; Schmidt D; Hornung J; Weidenthaler H; Heery CR; Meyer TPH; Silbernagl G; Maclennan J; Chaplin P
N Engl J Med; 2019 Nov; 381(20):1897-1908. PubMed ID: 31722150
[TBL] [Abstract][Full Text] [Related]
7. Modified vaccinia virus Ankara immunization protects against lethal challenge with recombinant vaccinia virus expressing murine interleukin-4.
McCurdy LH; Rutigliano JA; Johnson TR; Chen M; Graham BS
J Virol; 2004 Nov; 78(22):12471-9. PubMed ID: 15507634
[TBL] [Abstract][Full Text] [Related]
8. Percutaneous Vaccination as an Effective Method of Delivery of MVA and MVA-Vectored Vaccines.
Meseda CA; Atukorale V; Kuhn J; Schmeisser F; Weir JP
PLoS One; 2016; 11(2):e0149364. PubMed ID: 26895072
[TBL] [Abstract][Full Text] [Related]
9. Antibody profiling by proteome microarray reveals the immunogenicity of the attenuated smallpox vaccine modified vaccinia virus ankara is comparable to that of Dryvax.
Davies DH; Wyatt LS; Newman FK; Earl PL; Chun S; Hernandez JE; Molina DM; Hirst S; Moss B; Frey SE; Felgner PL
J Virol; 2008 Jan; 82(2):652-63. PubMed ID: 17977963
[TBL] [Abstract][Full Text] [Related]
10. Clinical and immunologic responses to multiple doses of IMVAMUNE (Modified Vaccinia Ankara) followed by Dryvax challenge.
Frey SE; Newman FK; Kennedy JS; Sobek V; Ennis FA; Hill H; Yan LK; Chaplin P; Vollmar J; Chaitman BR; Belshe RB
Vaccine; 2007 Dec; 25(51):8562-73. PubMed ID: 18036708
[TBL] [Abstract][Full Text] [Related]
11. Rapid protection in a monkeypox model by a single injection of a replication-deficient vaccinia virus.
Earl PL; Americo JL; Wyatt LS; Espenshade O; Bassler J; Gong K; Lin S; Peters E; Rhodes L; Spano YE; Silvera PM; Moss B
Proc Natl Acad Sci U S A; 2008 Aug; 105(31):10889-94. PubMed ID: 18678911
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with recombinant Modified Vaccinia Ankara (MVA) viruses expressing single African horse sickness virus VP2 antigens induced cross-reactive virus neutralising antibodies (VNAb) in horses when administered in combination.
Manning NM; Bachanek-Bankowska K; Mertens PPC; Castillo-Olivares J
Vaccine; 2017 Oct; 35(44):6024-6029. PubMed ID: 28438410
[TBL] [Abstract][Full Text] [Related]
13. E3L and F1L Gene Functions Modulate the Protective Capacity of Modified Vaccinia Virus Ankara Immunization in Murine Model of Human Smallpox.
Volz A; Jany S; Freudenstein A; Lantermann M; Ludwig H; Sutter G
Viruses; 2018 Jan; 10(1):. PubMed ID: 29300297
[TBL] [Abstract][Full Text] [Related]
14. Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge.
Wyatt LS; Earl PL; Eller LA; Moss B
Proc Natl Acad Sci U S A; 2004 Mar; 101(13):4590-5. PubMed ID: 15070762
[TBL] [Abstract][Full Text] [Related]
15. Mucosal immunization induces a higher level of lasting neutralizing antibody response in mice by a replication-competent smallpox vaccine: vaccinia Tiantan strain.
Lu B; Yu W; Huang X; Wang H; Liu L; Chen Z
J Biomed Biotechnol; 2011; 2011():970424. PubMed ID: 21765641
[TBL] [Abstract][Full Text] [Related]
16. Measurement of antibody responses to Modified Vaccinia virus Ankara (MVA) and Dryvax(®) using proteome microarrays and development of recombinant protein ELISAs.
Hermanson G; Chun S; Felgner J; Tan X; Pablo J; Nakajima-Sasaki R; Molina DM; Felgner PL; Liang X; Davies DH
Vaccine; 2012 Jan; 30(3):614-25. PubMed ID: 22100890
[TBL] [Abstract][Full Text] [Related]
17. Vaccine Inoculation Route Modulates Early Immunity and Consequently Antigen-Specific Immune Response.
Rosenbaum P; Tchitchek N; Joly C; Rodriguez Pozo A; Stimmer L; Langlois S; Hocini H; Gosse L; Pejoski D; Cosma A; Beignon AS; Dereuddre-Bosquet N; Levy Y; Le Grand R; Martinon F
Front Immunol; 2021; 12():645210. PubMed ID: 33959127
[TBL] [Abstract][Full Text] [Related]
18. Recombinant A27 protein synergizes with modified vaccinia Ankara in conferring protection against a lethal vaccinia virus challenge.
He Y; Meseda CA; Vassell RA; Merchlinsky M; Weir JP; Weiss CD
Vaccine; 2010 Jan; 28(3):699-706. PubMed ID: 19887133
[TBL] [Abstract][Full Text] [Related]
19. Smallpox vaccine, ACAM2000: Sites and duration of viral shedding and effect of povidone iodine on scarification site shedding and immune response.
Pittman PR; Garman PM; Kim SH; Schmader TJ; Nieding WJ; Pike JG; Knight R; Johnston SC; Huggins JW; Kortepeter MG; Korman L; Ranadive M; Quinn X; Meyers MS
Vaccine; 2015 Jun; 33(26):2990-6. PubMed ID: 25930115
[TBL] [Abstract][Full Text] [Related]
20. Development of eczema vaccinatum in atopic mouse models and efficacy of MVA vaccination against lethal poxviral infection.
Knitlova J; Hajkova V; Voska L; Elsterova J; Obrova B; Melkova Z
PLoS One; 2014; 9(12):e114374. PubMed ID: 25486419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
